Revolution Medicines CFO reports 10,000-share sale and option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Revolution Medicines (RVMD) reported an insider transaction on a Form 4. CFO Jack Anders exercised 10,000 stock options at $17 and sold 10,000 common shares at $64 on November 11, 2025 pursuant to a Rule 10b5-1 plan adopted on December 16, 2024.
After these transactions, Anders beneficially owned 110,994 shares, which include 48,275 restricted stock units. The option exercised related to an award with a $17 exercise price (exercisable from 02/12/2024 to 02/11/2030), with 5,418 derivative securities remaining beneficially owned.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 10,000 shares ($640,000)
Net Sell
3 txns
Insider
Anders Jack
Role
Chief Financial Officer
Sold
10,000 shs ($640K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $17.00 | $170K |
| Sale | Common Stock | 10,000 | $64.00 | $640K |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,418 shares (Direct);
Common Stock — 120,994 shares (Direct)
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024. Includes 48,275 restricted stock units.
FAQ
What insider transaction did RVMD’s CFO report?
CFO Jack Anders exercised 10,000 options at $17 and sold 10,000 shares at $64 on 11/11/2025.
Was the RVMD transaction under a 10b5-1 plan?
Yes. It was made pursuant to a Rule 10b5-1 plan adopted on 12/16/2024.
How many RSUs are included in the CFO’s ownership at RVMD?
His beneficial ownership includes 48,275 restricted stock units.
What was the exercise price and sale price in the RVMD Form 4?
Options were exercised at $17 per share, and shares were sold at $64 per share.
What option award details were disclosed for RVMD’s CFO?
The option had a $17 exercise price, exercisable from 02/12/2024 to 02/11/2030, with 5,418 derivative securities remaining owned.